A few years WHI study showed that menopausal women who received a standard dose of oral conjugated estrogens had less coronary artery calcification, a marker of plaque in the arteries, in comparison to women taking placebo. Coronary artery calcification is a predictor of possible future cardiovascular events.

Estrogen therapy is given, in addition to progestin, when the first menopausal symptoms occur.
Women under the age of 60 who were taking estrogen therapy had no coronary artery calcification. Also, there was no increase in coronary heart disease for women who had received hormone therapy within 10 years of menopause but a decrease of mortality among women aged 50-59 has been spotted.

However, scientists do not promote the use of estrogen therapy for the express purpose of preventing cardiovascular disease. They are only trying to help clarify the clinical perspective for women who choose hormone treatment for menopausal symptoms and prevention of osteoporosis. Hormonal therapy should be limited for controlling moderate to severe menopausal symptoms, with the lowest effective dose used for the shortest duration necessary.

Also, women should know that not all can receive the hormonal treatment. This is why it is essential to talk to their health care professionals to determine whether hormone therapy might be the right option for them.